CLINICAL RESEARCH: CORONARY ARTERY DISEASE
Intense Vasoconstriction in Response to Aspirate From Stented Saphenous Vein Aortocoronary Bypass Grafts
Kirsten Leineweber, PhD*,
Dirk Böse, MD ,
Magdalene Vogelsang, MSc*,
Michael Haude, MD, FACC,
Raimund Erbel, MD, FACC and
Gerd Heusch, MD, FACC*,*
* Institute of Pathophysiology, University of Essen School of Medicine, Essen, Germany
Department of Cardiology, University of Essen School of Medicine, Essen, Germany
Manuscript received March 29, 2005;
revised manuscript received September 29, 2005,
accepted October 10, 2005.
* Reprint requests and correspondence: Prof. Dr.med Dr.h.c. Gerd Heusch, Institute of Pathophysiology, University of Essen Medical School, Hufelandstrasse 55, 45147 Essen, Germany. (Email: gerd.heusch{at}uni-essen.de).
OBJECTIVES: We sought to identify soluble vasoconstrictor substances that are released during stent implantation into saphenous vein aortocoronary bypass grafts.
BACKGROUND: Atherosclerotic saphenous vein aortocoronary bypass grafts are particularly vulnerable to plaque rupture. Protection devices prevent particulate debris from being embolized. Additional soluble vasoconstrictor substances possibly also contribute to impaired microvascular perfusion.
METHODS: Peripheral venous blood (VB) and aspirate (AS) were obtained from 14 patients with a significant stenosis in a saphenous vein graft during stent implantation under protection with a distal balloon occlusion device. In five additional patients, arterial blood (AB) was also taken distal to the stented lesion before intervention. Vasomotor substances in VB, AB, and AS plasma were identified in a bioassay of rat mesenteric arteries with intact (+E) and denuded endothelium (–E). Vasoconstriction was normalized to that induced by potassium chloride depolarization (100%).
RESULTS: Venous blood, AB, and AS plasma induced maximum vasoconstriction within six minutes. The AS plasma induced a vasoconstriction of 138 ± 13% (–E) and 87 ± 14% (+E); VB, of 70 ± 14% (–E) and 23 ± 4% (+E); and AB plasma obtained before intervention, of 49 ± 9% (–E) and 36 ± 8% (+E). The vasoconstrictor potency of AS plasma in endothelium-denuded vessels was related to the severity of anginal symptoms, angiographic stenosis severity, plaque volume, and plaque burden as determined by intravascular ultrasound. The AS plasma-induced vasoconstriction was largely attenuated by combined serotonin/5-hydroxytryptamine (5-HT)2A/2C- and 5-HT1A/1B-receptor blockade and eliminated by additional thromboxane A2 thromboxane-prostanoid (TP)-receptor blockade.
CONCLUSIONS: Stent implantation releases, apart from and in addition to particulate debris, soluble vasoconstrictor substances that possibly contribute to impaired microvascular perfusion.
|
Abbreviations and Acronyms
| | 5-HT = 5-hydroxytryptamine | | AB = arterial blood | | AS = aspirate | | IVUS = intravascular ultrasound | | VB = venous blood |
|
This article has been cited by other articles:
|
|
|
|
 
G. Heusch, P. Kleinbongard, A. Skyschally, B. Levkau, R. Schulz, and R. Erbel
The coronary circulation in cardioprotection: more than just one confounder
Cardiovasc Res,
November 9, 2011;
(2011)
cvr271v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kleinbongard, D. Bose, T. Baars, S. Mohlenkamp, T. Konorza, S. Schoner, M. Elter-Schulz, H. Eggebrecht, H. Degen, M. Haude, et al.
Vasoconstrictor Potential of Coronary Aspirate From Patients Undergoing Stenting of Saphenous Vein Aortocoronary Bypass Grafts and Its Pharmacological Attenuation
Circ. Res.,
February 4, 2011;
108(3):
344 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. van Gaal and A. P. Banning
Chapter 37 Distal protection
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Tsimikas
High-Dose Statins Prior to Percutaneous Coronary Intervention: A Paradigm Shift to Influence Clinical Outcomes in the Cardiac Catheterization Laboratory
J. Am. Coll. Cardiol.,
December 1, 2009;
54(23):
2164 - 2166.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Heusch, P. Kleinbongard, D. Bose, B. Levkau, M. Haude, R. Schulz, and R. Erbel
Coronary Microembolization: From Bedside to Bench and Back to Bedside
Circulation,
November 3, 2009;
120(18):
1822 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Breuckmann, K. Nassenstein, C. Bucher, I. Konietzka, G. Kaiser, T. Konorza, C. Naber, A. Skyschally, P. Gres, G. Heusch, et al.
Systematic analysis of functional and structural changes after coronary microembolization: a cardiac magnetic resonance imaging study.
J. Am. Coll. Cardiol. Img.,
February 1, 2009;
2(2):
121 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Pepine
Provoked Coronary Spasm and Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
528 - 530.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bose, K. Leineweber, T. Konorza, A. Zahn, M. Brocker-Preuss, K. Mann, M. Haude, R. Erbel, and G. Heusch
Release of TNF-{alpha} during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis
Am J Physiol Heart Circ Physiol,
May 1, 2007;
292(5):
H2295 - H2299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bahrmann, G. S. Werner, G. Heusch, M. Ferrari, T. C. Poerner, A. Voss, and H. R. Figulla
Detection of Coronary Microembolization by Doppler Ultrasound in Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Interventions
Circulation,
February 6, 2007;
115(5):
600 - 608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hizume, K. Morikawa, A. Takaki, K. Abe, K. Sunagawa, M. Amano, K. Kaibuchi, C. Kubo, and H. Shimokawa
Sustained Elevation of Serum Cortisol Level Causes Sensitization of Coronary Vasoconstricting Responses in Pigs In Vivo: A Possible Link Between Stress and Coronary Vasospasm
Circ. Res.,
September 29, 2006;
99(7):
767 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
